Fungemia diseminada por Saprochaete clavata

Fernández, I.; Botello, Laura Nájera; Martínez, Beatriz Orden; Gullón, Gastón Roustán

doi:10.1016/j.eimc.2018.05.003

Cited by 8 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S. clavata is almost exclusively confined to systemic, life-threatening infections while the clinical presentation of infections caused by other arthroconidial fungi range from superficial ( Trichosporon spp. ), mucosal ( Galactomyces candidus ), allergic ( Trichosporon pneumonitis) to systemic forms ( T. asahii, M. capitatus , and G. candidus ) (Girmenia et al, 2005; Henrich et al, 2009; Bonifaz et al, 2010; Vaux et al, 2014; de Almeida Júnior and Hennequin, 2016; Durán Graeff et al, 2017; Esposto et al, 2018; Leoni et al, 2018; Salgüero Fernández et al, 2018). AML is the leading underlying condition for systemic infections caused by S. clavata such as for other arthroconidial yeasts (Girmenia et al, 2005; Henrich et al, 2009; Camus et al, 2014; de Almeida Júnior and Hennequin, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…That can suggest influence of some unknown epidemiological factor(s). All arthroconidial fungi are ubiquitous in nature but Trichosporon infections are more frequently described in the United States, while M. capitatus prevails in the Mediterranean area (Italy, France, Spain, Turkey, Greece, Tunisia, Israel, Libya, FungiScope ® ) (Schiemann et al, 1998; Gadea et al, 2004; Christakis et al, 2005; Girmenia et al, 2005; García-Ruiz et al, 2013; Vaux et al, 2014; Trabelsi et al, 2015; Del Principe et al, 2016; Durán Graeff et al, 2017; Esposto et al, 2018; Leoni et al, 2018; Salgüero Fernández et al, 2018). We found no correlation between temperature in the Czechia and in Eastern Bohemia and the number of isolated S. clavata strains during the follow-up period (data not shown).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Saprochaete clavata Invasive Infections – A New Threat to Hematological-Oncological Patients

et al. 2019

View full text Add to dashboard Cite

BackgroundSaprochaete clavata (formerly Geotrichum clavatum, now proposed as Magnusiomyces clavatus) is a filamentous yeast-like fungus that has recently been described as an emerging pathogen mostly in patients with acute leukemia.MethodsThis is a retrospective study of patients diagnosed with proven and probable S. clavata infection at the University Hospital, Hradec Králové, Czechia between March 2005 and December 2017. Previous cases were identified from the literature and FungiScope® database.ResultsSix new cases (5 females, 1 male) of blood-stream S. clavata infections at the hemato-oncological department were described including epidemiological data of additional 48 patients colonized with the species. Overall, 116 strains of S. clavata were isolated from different clinical specimens of 54 patients; most of them belonged to the respiratory tract (60.3%). S. clavata was the most frequent species among arthroconidial yeasts (Trichosporon, Galactomyces, Magnusiomyces) recovered from the blood. All our patients with S. clavata infection had profound neutropenia, a central venous catheter, broad-spectrum antibiotics and antifungal prophylaxis; four had a history of a biliary tract system disease. The diagnosis was based on a positive blood culture in all patients. Four patients died of multiorgan failure and sepsis despite treatment with lipid-based amphotericin B and/or voriconazole. From the literature and FungiScope database, 67 previous cases of S. clavata infections were evaluated in context of our cases.ConclusionSaprochaete clavata infection represents a life-threatening mycosis in severely immunocompromised patients. The successful outcome of treatment seems to be critically dependent on the early diagnosis and the recovery of underlying conditions associated with immune dysfunction or deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Saprochaete clavata Invasive Infections – A New Threat to Hematological-Oncological Patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Rare fungi as arthroconidial yeasts are diffuse globally, even if infections due to Trichosporon are prevalently reported in the United States, while those determined by Saprochaete capitata and Saprochaete clavata were mostly found in the Mediterranean area [8,19,29,[33][34][35][36][37][38][39][40]. This underlines that climatic factors might have a role in determining the epidemiology of these pathogens.…”

Section: Discussionmentioning

confidence: 99%

Management of Invasive Infections due to a Rare Arthroconidial Yeast, Saprochaete capitata, in Two Patients with Acute Hematological Malignancies

et al. 2021

View full text Add to dashboard Cite

Saprochaete capitata is an arthroconidial yeast, found principally in the environment, even if it belongs also to the normal microbial flora that colonize human subjects. This yeast is increasingly associated with invasive infections in hematological patients, in particular in those affected by acute leukemia. An important risk factor that predisposes to this infection is the profound neutropenia present in such immunocompromised patients. Saprochaete spp. were found resistant to both echinocandins and fluconazole so the treatment is often difficult. Here, we report two cases of sepsis in two patients with acute leukemia. All of them had fatal events, due to the worsening of their clinical condition. An early diagnosis and appropriate management of these pathogens is important in consideration of the poor prognosis associated to these fungal invasive infections.

show abstract

Fungaemia due to rare yeasts in a tertiary care university centre within 18 years

Alp

Gülmez

Ayaz

et al. 2020

Mycoses

View full text Add to dashboard Cite

Background: Fungaemia due to rare yeasts has been recognised as an emerging, clinically relevant, but less investigated condition. Intrinsic resistance or reduced susceptibility of these species to echinocandins or fluconazole remains as a challenge in empirical treatment. Objectives:To describe the clinical characteristics, administered antifungal agents, outcomes of patients with rare yeasts other than Candida (RY-OTC) fungaemia and determine the antifungal susceptibility profiles of the isolates. Patients and methods: RY-OTC fungaemia between January-2001 andDecember-2018 were retrospectively evaluated. Antifungal susceptibility tests were performed according to CLSI M27-A3. Results:We identified 19 patients with fungaemia due to 20 RY-OTC (8 Trichosporon asahii, 4 Cryptococcus neoformans, 4 Saprochaete capitata, 3 Rhodotorula mucilaginosa, 1 Trichosporon mucoides) with an incidence of 2.2% among 859 fungaemia episodes.Haematological malignancy was the most common (42%) underlying disorder. In 6 patients, RY-OTC fungaemia developed as breakthrough infection while receiving echinocandins, amphotericin B or fluconazole. Amphotericin B, fluconazole or voriconazole were the drugs of choice for the initial treatment of breakthrough fungaemia. Among patients without previous exposure to antifungals, the most common empirical treatment was an echinocandin (50%), followed by fluconazole (42%) and amphotericin B (8%). Overall mortality was 47%. Worse outcome was most common among patients receiving echinocandins (83% vs 25%, P < .05). Voriconazole and posaconazole showed the highest in vitro activity against all the isolates tested. Amphotericin B MICs were relatively higher and the degree of activity of fluconazole and itraconazole was variable. Conclusions: Early recognition of RY-OTC and knowledge about their susceptibility patterns remain crucial in initial treatment pending susceptibility data of isolates. K E Y W O R D S amphotericin B, antifungal resistance, antifungal treatment, azoles, breakthrough fungaemia, echinocandins, fungaemia, rare yeast | 489 ALP et AL.

show abstract

Fungemia diseminada por Saprochaete clavata

Cited by 8 publications

References 5 publications

Saprochaete clavata Invasive Infections – A New Threat to Hematological-Oncological Patients

Saprochaete clavata Invasive Infections – A New Threat to Hematological-Oncological Patients

Management of Invasive Infections due to a Rare Arthroconidial Yeast, Saprochaete capitata, in Two Patients with Acute Hematological Malignancies

Fungaemia due to rare yeasts in a tertiary care university centre within 18 years

Contact Info

Product

Resources

About